-
Immunotherapy for metastatic non-small cell lung cancer [Elektronski vir] : real-world data from an academic Central and Eastern European centerIvanović, Marija, zdravnica ...Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first ... results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.Source: The oncologist [Elektronski vir]. - ISSN 1549-490X (Vol. 26, iss. 12, Dec. 2021, str. e2143-e2150)Type of material - e-article ; adult, seriousPublish date - 2021Language - englishCOBISS.SI-ID - 76794115
Author
Ivanović, Marija, zdravnica |
Knez, Lea, 1981- |
Herzog, Ana |
Kovačević, Mile |
Čufer, Tanja, 1955-
Topics
Carcinoma, non-small cell lung |
Immunotherapy |
Nedrobnocelični karcinom pljuč |
Imunoterapija |
Europe |
Europe, Eastern |
Evropa |
Vzhodna Evropa |
napredovali nedrobnocelinčni karcinom pljuč |
podatki iz resničnega življenja |
srednja Evropa |
advanced non-small cell lung cancer |
real-world data |
Central Europe
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Ivanović, Marija, zdravnica | ![]() |
Knez, Lea, 1981- | 29281 |
Herzog, Ana | ![]() |
Kovačević, Mile | ![]() |
Čufer, Tanja, 1955- | 12179 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.